The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)

Lim, KJ; Wellard, C; Talaulikar, D; Tan, JL; Loh, J; Puvanakumar, P; Kuzich, JA; Ho, M; Murphy, M; Zeglinas, N; Low, MSY; Routledge, D; Lim, ABM; Gibbs, SD; Quach, H; Morgan, S; Moore, E; Ninkovic, S

Author(s): Lim, KJ; Wellard, C; Talaulikar, D; Tan, JL; Loh, J; Puvanakumar, P; Kuzich, JA; Ho, M; Murphy, M; Zeglinas, N; Low, MSY; Routledge, D; Lim, ABM; Gibbs, SD; Quach, H; Morgan, S; Moore, E; Ninkovic, S;
Details: Publication Year 2023-08,Volume 4,Issue #3,Page 639-646
Journal Title: eJHaem
Publication Type: Research article
Abstract: The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort study using real-world data to interrogate treatment patterns and outcomes in 74 MM patients with t(11;14) [t(11;14)-MM] diagnosed over 10 years. This was compared to 159 and 111 MM patients with high-risk IgH translocations (IgH HR-MM) and hyperdiploidy (Hyperdiploid-MM), respectively, from the Australian Myeloma and Related Diseases Registry. No appreciable differences in age, gender, ISS, LDH levels, 1q21 or del(17p) status, or treatment patterns were observed between groups. Median PFS-1 was not different between groups but both t(11;14)-MM and IgH HR-MM had an inferior PFS-2 vs. Hyperdiploid-MM: median PFS-2 8.2 months, 10.0 months, and 19.8 months (p = 0.002), respectively. The 3-year OS were 69%, 71%, and 82% (p = 0.026), respectively. In the t(11;14)-MM group, gain or amplification of 1q21 at diagnosis predicted for poorer OS (HR 3.46, p = 0.002). Eleven patients had received venetoclax with 45% achieving better than a very good partial response. Results suggest that t(11;14) MM may confer an unfavorable risk profile and that the use of targeted therapies such as venetoclax earlier in the treatment algorithm should be explored.
Publisher: Wiley
Keywords: Bcl2; multiple myeloma; t(11; 14); venetoclax
Department(s): Clinical Haematology
PubMed ID: 37601874
Publisher's Version: https://doi.org/10.1002/jha2.742
Open Access at Publisher's Site: https://doi.org/10.1002/jha2.742
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-11-02 06:14:34

Last Modified: 2023-11-02 06:19:00